Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 4, 2000, Pages 463-469

  Lo, I ^a,b   Castro, ^c   Diago, ^d   Moreno, ^a   Fernandez Bermejo, ^a   Vega, ^c   Garcia ^d   Carbonell, ^d   Sanz, ^a   Borque, ^a   Garcia Buey ^a   Garcia Monzon ^a   Pedreira, ^c   Moreno Otero, R ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF PALERMO   (Italy)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; ASTHMA; CLINICAL TRIAL; COUGHING; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VIRUS STRAIN;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL;

EID: 1642534012     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00713.x     Document Type: Article

References (29)

1. 1 National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997; 26(Suppl. 1): S2-10.
2. 2 Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(Suppl. 1): S62-5.
3. 3 WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341-4.
4. 4 Poynard T, Bedossa P, Opolon P. for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
5. 5 Tiné F, Magrin S, Craxí A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991; 13: 192-9.
6. 6 Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1996; 332: 1457-62. (Erratum, N Engl J Med 1996; 334: 1143).
7. 7 Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.
8. 8 Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997; 26(Suppl. 1): S137-42.
9. 9 McHutchinson JG, Gordon SC, Schiff ER, et al. for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
10. 10 Davis GL, Esteban-Mur R, Rustgi V, et al. for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
11. 11 Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks vs. interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
12. 12 Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: meta-analysis of individual patient data from European centers. J Hepatol 1997; 26: 961-6.
13. 13 Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G. Ribavirin and interferon-alpha combination therapy vs. interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepatol 1997; 4: 185-91.
14. 14 Scotto G, Fazio V, Tantimonaco G. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J Gastroenterol 1996; 28: 505-11.
15. 15 Sostegni R, Ghisetti V, Pittaluga F, et al. Sequential vs. concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology 1998; 28: 341-5.
16. 16 Wedemeyer H, Caselmann WH, Manns MP. Combination therapy of chronic hepatitis C: an important step but not final goal! J Hepatol 1998; 29: 1010-14.
17. 17 Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 5: 431-5.
18. 18 Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26(Suppl. 1): S71-7.
19. 19 BMDP Statistical Software Manual. LR Stepwise logistic regression, vol. 2, 1992: 1105.
20. 20 Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alfa 2 a interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6.
21. 21 Davis GL, Lau JYN. Factors predictive of beneficial response to therapy of hepatitis C. Hepatology 1997; 26(Suppl. 1): S122-7.
22. 22 Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-31.
23. 23 Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999; 117: 408-13.
24. 24 Andreone P, Gramenzi A, Cursaro C, et al. Interferon-α plus ribavirin in chronic hepatitis C resistant to previous interferon-α course: results of a randomized multicenter trial. J Hepatol 1999; 30: 788-93.
25. 25 Interferon alpha-2b, ribavirin in combination for patients with chronic hepatitis C, who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am J Med 1999; 107: 112-18.
26. 26 Marcellin P, Boyer N, Gervais A, et al. Long-term histologie improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy. Ann Intern Med 1997; 127: 875-81.
27. 27 Lau DT-Y, Kleiner DE, Ghany MG, Schimd P, Hoofnagle JH. Sustained virologie response to interferon alfa in chronic hepatitis C is associated with long-term histologie improvement and lack of hepatic HCV RNA. Gastroenterology 1998; 114(Suppl.): A1284(Abstract).
28. 28 Brouwer JT, Hansen BE, Niesters HGM, Schalm SW. Early prediction of response in interferon monotherapy and interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30: 192-8.
29. 29 EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30: 956-61.